Market Price

80.49 

0.06 0.1%

as of Mar 21 '19

52 Week Range:

75.77 107.25


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune diseases; IMBRUVICA, an oral therapy for treating chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C. It also provides Kaletra, an anti- human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid for hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; and ZINBRYTA, a treatment for relapsing forms of multiple sclerosis. It serves wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers. AbbVie Inc. has collaborations with Alector, Inc.; C2N Diagnostics; Voyager Therapeutics, Inc.; Janssen Biotech, Inc.; International Myeloma Foundation; Calibr and Scripps Research; The Institute for Research in Immunology and Cancer – Commercialization of Research; the Université de Montréal; Tolero Pharmaceuticals, Inc.; Galapagos; Mission Therapeutics Ltd; Bristol-Myers Squibb Company; Voluntis; Tizona Therapeutics, Inc.; and Voyager Therapeutics, Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Equity (BVPS) 0.00
0.00
9.93
7.55
2.13
2.25
2.92
3.02
4.06
4.20
-1.98
growth rate -24.0% -71.8% 5.6% 29.8% 3.4% 34.4% 3.5% -100.0%
Earnings BIT 0.00
5,950.00
4,840.00
3,670.00
6,967.00
6,528.00
5,500.00
8,856.00
9,623.00
10,643.00
11,911.00
growth rate -18.7% -24.2% 89.8% -6.3% -15.8% 61.0% 8.7% 10.6% 11.9%
Avg.PE 0.00
10.21
20.53
55.00
17.89
17.10
35.98
21.99
growth rate 101.1% 167.9% -67.5% -4.4% 110.4% -38.9%
ROA 0.00
29.20
19.77
16.83
22.61
14.69
6.25
12.76
9.94
7.72
8.69
growth rate -32.3% -14.9% 34.3% -35.0% -57.5% 104.2% -22.1% -22.3% 12.6%
ROE 0.00
0.00
26.61
24.59
67.69
105.11
56.91
180.90
138.05
108.56
growth rate -7.6% 175.3% 55.3% -45.9% 217.9% -23.7% -21.4%
ROIC 26.45
24.59
22.81
22.71
11.49
21.66
17.27
14.24
growth rate -7.0% -7.2% -0.4% -49.4% 88.5% -20.3% -17.5%
Cur. Ratio 2.19
1.25
2.27
2.59
1.41
1.50
1.65
1.28
0.98
growth rate -42.9% 81.6% 14.1% -45.6% 6.4% 10.0% -22.4% -23.4%
Quick Ratio 0.90
0.76
1.81
2.14
1.11
1.21
1.14
0.89
0.78
growth rate -15.6% 138.2% 18.2% -48.1% 9.0% -5.8% -21.9% -12.4%
Leverage 1.35
1.61
8.03
6.50
15.81
13.45
14.26
13.89
growth rate 19.3% 398.8% -19.1% 143.2% -14.9% 6.0% -2.6%
Balance Sheet Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Acct.Receivable 0.00
0.00
3,373.10
5,286.00
3,602.00
0.00
3,735.00
4,730.00
5,105.00
7,188.00
5,872.00
growth rate 56.7% -31.9% -100.0% 26.6% 7.9% 40.8% -18.3%
Acct.Payable 5,881.00
3,095.00
2,334.00
1,401.00
1,597.00
1,407.00
1,474.00
1,546.00
growth rate -47.4% -24.6% -40.0% 14.0% -11.9% 4.8% 4.9%
Cur.Assets 0.00
0.00
8,218.49
7,354.00
15,354.00
17,848.00
16,081.00
16,314.00
16,187.00
21,223.00
16,945.00
growth rate -10.5% 108.8% 16.2% -9.9% 1.5% -0.8% 31.1% -20.2%
Total Assets 16,601.00
15,858.00
21,134.71
19,521.00
27,008.00
29,198.00
27,513.00
53,050.00
66,099.00
70,786.00
59,352.00
growth rate -4.5% 33.3% -7.6% 38.4% 8.1% -5.8% 92.8% 24.6% 7.1% -16.2%
Cash 0.00
0.00
10.78
27.00
5,901.00
9,595.00
8,348.00
8,399.00
5,100.00
9,303.00
7,289.00
growth rate 150.5% 21,755.6% 62.6% -13.0% 0.6% -39.3% 82.4% -21.7%
Inventory 0.00
0.00
836.27
872.00
258.00
261.00
1,124.00
1,719.00
1,444.00
1,605.00
1,605.00
growth rate 4.3% -70.4% 1.2% 330.7% 52.9% -16.0% 11.2% 0.0%
Cur.Liabilities 0.00
0.00
3,761.25
5,897.00
6,776.00
6,879.00
11,393.00
10,894.00
9,781.00
16,641.00
17,239.00
growth rate 56.8% 14.9% 1.5% 65.6% -4.4% -10.2% 70.1% 3.6%
Liabilities 0.00
0.00
5,431.71
7,589.00
23,645.00
24,706.00
25,771.00
49,105.00
61,463.00
65,689.00
67,798.00
growth rate 39.7% 211.6% 4.5% 4.3% 90.5% 25.2% 6.9% 3.2%
LT Debt 0.00
0.00
0.00
32.00
14,630.00
0.00
10,538.00
29,321.00
36,440.00
30,953.00
35,002.00
growth rate 45,618.8% -100.0% 178.2% 24.3% -15.1% 13.1%
Equity 0.00
0.00
15,703.00
11,932.00
3,363.00
4,492.00
1,742.00
3,945.00
4,636.00
5,097.00
-8,446.00
growth rate -24.0% -71.8% 33.6% -61.2% 126.5% 17.5% 9.9% -100.0%
Common Shares 1,580.67
1,580.00
1,580.00
1,580.00
1,577.00
1,604.00
1,610.00
1,637.00
1,631.00
1,603.00
1,546.00
growth rate 0.0% 0.0% 0.0% -0.2% 1.7% 0.4% 1.7% -0.4% -1.7% -3.6%
Cash Flow Statement Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Capital Expenditures 0.00
312.60
448.00
356.00
333.00
491.00
612.00
532.00
479.00
529.00
638.00
growth rate 43.3% -20.5% -6.5% 47.5% 24.6% -13.1% -10.0% 10.4% 20.6%
Cash Dividends 0.00
0.00
0.00
0.00
0.00
2,555.00
2,661.00
3,294.00
3,717.00
4,107.00
5,580.00
growth rate 4.2% 23.8% 12.8% 10.5% 35.9%
Cash From OA 0.00
5,367.30
4,976.00
6,247.00
6,345.00
6,267.00
3,549.00
7,535.00
7,041.00
9,960.00
13,427.00
growth rate -7.3% 25.5% 1.6% -1.2% -43.4% 112.3% -6.6% 41.5% 34.8%
FCF per Share 3.81
3.47
2.96
2.73
4.25
5.26
7.58
growth rate -8.9% -14.7% -7.8% 55.7% 23.8% 44.1%
Sale Purchase of Stock 0.00
-320.00
232.00
155.00
268.00
254.00
growth rate 100.0% -33.2% 72.9% -5.2%
FCF 0.00
5,055.00
4,528.00
5,891.00
6,012.00
5,776.00
2,937.00
7,003.00
6,562.00
9,431.00
12,789.00
growth rate -10.4% 30.1% 2.1% -3.9% -49.2% 138.4% -6.3% 43.7% 35.6%
Income Statement Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Sales 14,179.00
14,214.20
15,638.00
17,444.00
18,380.00
18,790.00
19,960.00
22,859.00
25,638.00
28,216.00
32,753.00
growth rate 0.3% 10.0% 11.6% 5.4% 2.2% 6.2% 14.5% 12.2% 10.1% 16.1%
Op.Income 0.00
4,931.80
4,717.00
3,433.00
5,275.00
4,128.00
5,500.00
8,856.00
9,623.00
10,643.00
11,911.00
growth rate -4.4% -27.2% 53.7% -21.7% 33.2% 61.0% 8.7% 10.6% 11.9%
IBT 0.00
5,950.30
4,836.00
3,668.00
5,725.00
5,332.00
2,369.00
6,645.00
7,884.00
7,727.00
5,197.00
growth rate -18.7% -24.2% 56.1% -6.9% -55.6% 180.5% 18.7% -2.0% -32.7%
Net Income 0.00
4,636.50
4,178.00
3,433.00
5,275.00
4,128.00
1,774.00
5,144.00
5,953.00
5,309.00
5,687.00
growth rate -9.9% -17.8% 53.7% -21.7% -57.0% 190.0% 15.7% -10.8% 7.1%
EPS 0.00
0.00
2.65
2.18
3.35
2.56
1.10
3.13
3.63
3.30
3.66
growth rate -17.7% 53.7% -23.6% -57.0% 184.6% 16.0% -9.1% 10.9%
Gross Profit 0.00
10,157.80
11,345.00
12,805.00
15,022.00
14,209.00
15,571.00
18,620.00
19,845.00
21,528.00
25,035.00
growth rate 11.7% 12.9% 17.3% -5.4% 9.6% 19.6% 6.6% 8.5% 16.3%
R&D 1,707.40
2,808.00
2,618.00
3,066.00
3,193.00
3,297.00
4,101.00
4,385.00
5,007.00
5,259.00
growth rate 64.5% -6.8% 17.1% 4.1% 3.3% 24.4% 6.9% 14.2% 5.0%

Quarterly Statements

Item Name Dec '17 Mar '18 Jun '18 Sep '18 Dec '18
Earnings BIT 2,733.00
3,090.00
2,775.00
3,222.00
2,937.00
growth rate 13.1% -10.2% 16.1% -8.9%
Balance Sheet Dec '17 Mar '18 Jun '18 Sep '18 Dec '18
Acct.Receivable 7,188.00
5,841.00
5,793.00
5,780.00
5,872.00
growth rate -18.7% -0.8% -0.2% 1.6%
Acct.Payable 1,474.00
10,542.00
10,337.00
10,981.00
1,546.00
growth rate 615.2% -1.9% 6.2% -85.9%
Cur.Assets 21,223.00
20,444.00
13,845.00
18,465.00
16,945.00
growth rate -3.7% -32.3% 33.4% -8.2%
Total Assets 70,786.00
69,342.00
61,641.00
66,164.00
59,352.00
growth rate -2.0% -11.1% 7.3% -10.3%
Cash 9,303.00
9,007.00
3,547.00
8,015.00
7,289.00
growth rate -3.2% -60.6% 126.0% -9.1%
Inventory 1,605.00
1,738.00
1,580.00
1,786.00
1,605.00
growth rate 8.3% -9.1% 13.0% -10.1%
Cur.Liabilities 16,641.00
17,058.00
17,224.00
15,387.00
17,239.00
growth rate 2.5% 1.0% -10.7% 12.0%
Liabilities 65,689.00
65,789.00
65,016.00
69,085.00
67,798.00
growth rate 0.2% -1.2% 6.3% -1.9%
LT Debt 30,953.00
31,481.00
31,216.00
37,187.00
35,002.00
growth rate 1.7% -0.8% 19.1% -5.9%
Equity 5,097.00
3,553.00
-3,375.00
-2,921.00
-8,446.00
growth rate -30.3% -100.0% 0.0% 0.0%
Common Shares 18.00
18.00
18.00
18.00
18.00
growth rate 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Dec '17 Mar '18 Jun '18 Sep '18 Dec '18
Capital Expenditures 182.00
119.00
114.00
282.00
123.00
growth rate -34.6% -4.2% 147.4% -56.4%
Cash Dividends 1,030.00
1,137.00
1,531.00
1,461.00
1,451.00
growth rate 10.4% 34.7% -4.6% -0.7%
Cash From OA 2,584.00
2,645.00
2,866.00
4,524.00
3,392.00
growth rate 2.4% 8.4% 57.9% -25.0%
Sale Purchase of Stock 40.00
62.00
growth rate 55.0%
FCF 2,402.00
2,526.00
2,752.00
4,242.00
3,269.00
growth rate 5.2% 9.0% 54.1% -22.9%
Income Statement Dec '17 Mar '18 Jun '18 Sep '18 Dec '18
Sales 7,739.00
7,934.00
8,278.00
8,236.00
8,305.00
growth rate 2.5% 4.3% -0.5% 0.8%
Op.Income 2,733.00
3,090.00
2,775.00
3,222.00
2,937.00
growth rate 13.1% -10.2% 16.1% -8.9%
IBT 1,193.00
2,797.00
2,012.00
2,761.00
-2,373.00
growth rate 134.5% -28.1% 37.2% -100.0%
Net Income 52.00
2,783.00
1,983.00
2,747.00
-1,826.00
growth rate 5,251.9% -28.8% 38.5% -100.0%
EPS
growth rate
Gross Profit 5,813.00
6,007.00
6,344.00
6,401.00
6,283.00
growth rate 3.3% 5.6% 0.9% -1.8%
R&D 1,402.00
1,244.00
1,322.00
1,268.00
1,425.00
growth rate -11.3% 6.3% -4.1% 12.4%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

C (53.62)

YOY Growth Grade:

D (39.54)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 22.04 21.99 8.55
EPS / Growth 16.8% 3.66 16.8%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 1.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 1.0% 11.5% 11.5%
Future PE 2.00 17.89 17.89
Future EPS 4.04 10.91 10.91
Value Price
MOS %
2.00
-97.5%
48.24
-40.1%
48.24
-40.1%
MOS Price 1.00 24.12 24.12
IRT 19.80 10.86 10.86

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.